(Q37590663)

21 August 2017

1 reference

title

Biological fluid biomarkers in neurodegenerative parkinsonism (English)

1 reference

21 August 2017

0 references

1 reference

1 reference

David R Williams

2

0 references

author name string

Michael Eller

series ordinal

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

published in

Nature Reviews Neurology

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

561-570

1 reference

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Accuracy of clinical diagnosis of progressive supranuclear palsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

How valid is the clinical diagnosis of Parkinson's disease in the community?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Alpha-synuclein in Lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Diffuse Lewy body disease in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Dementia with Lewy bodies: diagnosis and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Cerebrospinal fluid Abeta42 levels in multiple system atrophy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Tau protein pathology in neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Neuropathology of Alzheimer's disease and related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Biomarkers for cognitive impairment and dementia in elderly people.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Multiple-system atrophy: a new alpha-synuclein disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Corticodentatonigral Degeneration With Neuronal Achromasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Pathologic heterogeneity in clinically diagnosed corticobasal degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Clinicopathological correlates in frontotemporal dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

CSF biomarkers in frontotemporal lobar degeneration with known pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

CSF neurofilament proteins in the differential diagnosis of dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Shunt responsive progressive supranuclear palsy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Prevalence of Alzheimer's disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Tau protein is a potential biological marker for normal pressure hydrocephalus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

International quality control survey of neurochemical dementia diagnostics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Plasma urate and risk of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Serum uric acid levels and the risk of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Gout and risk of Parkinson disease: A prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Metabolomic profiling to develop blood biomarkers for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Red blood cells are the major source of alpha-synuclein in blood.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Parkinson patient fibroblasts show increased alpha-synuclein expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Biomarkers and Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

The diagnosis of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Second consensus statement on the diagnosis of multiple system atrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.135

Accuracy of clinical diagnosis in parkinsonism--a prospective study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19724250

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2009.135

1 reference

21 August 2017

1 reference